PolyPeptide Group AG
Symbol: PPGN.SW
SIX
30.85
CHFMarkedspris i dag
-20.2422
P/E-forhold
-0.4777
PEG Ratio
1.02B
MRK Cap
- 0.00%
DIV Udbytte
PolyPeptide Group AG (PPGN-SW) Årsregnskaber
Balance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 208.66 | 95.7 | 37.5 | 136.3 | ||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.net-receivables | 279.04 | 101.1 | 49.1 | 67.8 | ||||||
balance-sheet.row.inventory | 564.08 | 128.5 | 145.1 | 113 | ||||||
balance-sheet.row.other-current-assets | 71.69 | 1.3 | 19.8 | 14.5 | ||||||
balance-sheet.row.total-current-assets | 1123.47 | 326.6 | 251.6 | 331.6 | ||||||
balance-sheet.row.property-plant-equipment-net | 1190.14 | 324.1 | 297.3 | 235.4 | ||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.intangible-assets | 63.7 | 16.5 | 15.9 | 14.3 | ||||||
balance-sheet.row.goodwill-and-intangible-assets | 63.7 | 16.5 | 15.9 | 14.3 | ||||||
balance-sheet.row.long-term-investments | 13.32 | 5.2 | 2.8 | 3.5 | ||||||
balance-sheet.row.tax-assets | 42.61 | 16.7 | 8.3 | 10.3 | ||||||
balance-sheet.row.other-non-current-assets | -25.92 | 0 | -8.3 | -10.3 | ||||||
balance-sheet.row.total-non-current-assets | 1283.86 | 362.5 | 315.9 | 253.2 | ||||||
balance-sheet.row.other-assets | 25.92 | 0 | 8.3 | 10.3 | ||||||
balance-sheet.row.total-assets | 2433.25 | 689.1 | 575.8 | 595 | ||||||
balance-sheet.row.account-payables | 160.69 | 60.9 | 45.9 | 28.5 | ||||||
balance-sheet.row.short-term-debt | 111.1 | 45.7 | 3.6 | 3.1 | ||||||
balance-sheet.row.tax-payables | 17.52 | 9.3 | 4.9 | 7.6 | ||||||
balance-sheet.row.long-term-debt-total | 97 | 68 | 9.4 | 10.3 | ||||||
Deferred Revenue Non Current | 47.26 | 23.2 | 7.5 | 9.2 | ||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 8.59 | - | - | - | ||||||
balance-sheet.row.other-current-liab | 237.3 | 1.4 | 50.1 | 75.5 | ||||||
balance-sheet.row.total-non-current-liabilities | 160.46 | 131.4 | 9.4 | 10.3 | ||||||
balance-sheet.row.other-liabilities | 146.11 | 0 | 48.6 | 59.6 | ||||||
balance-sheet.row.capital-lease-obligations | 87.25 | 23.3 | 21.2 | 18 | ||||||
balance-sheet.row.total-liab | 818.72 | 307.9 | 154.1 | 173.9 | ||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.common-stock | 1.21 | 0.3 | 0.3 | 0.3 | ||||||
balance-sheet.row.retained-earnings | 775.36 | 165.1 | 214.1 | 196 | ||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 74.69 | 23 | 17.7 | 13.2 | ||||||
balance-sheet.row.other-total-stockholders-equity | 763.27 | 192.7 | 189.5 | 211.6 | ||||||
balance-sheet.row.total-stockholders-equity | 1614.53 | 381.2 | 421.7 | 421.2 | ||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 2433.25 | 689.1 | 575.8 | 595 | ||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.total-equity | 1614.53 | 381.2 | 421.7 | 421.2 | ||||||
balance-sheet.row.total-liabilities-and-total-equity | 2433.25 | - | - | - | ||||||
Total Investments | 13.32 | 5.2 | 2.8 | 3.5 | ||||||
balance-sheet.row.total-debt | 232.77 | 113.7 | 21.2 | 18 | ||||||
balance-sheet.row.net-debt | 24.11 | 18 | -16.3 | -118.3 |
Pengestrømsopgørelse
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -43.67 | -51.4 | 7.8 | 47.3 | ||||||
cash-flows.row.depreciation-and-amortization | 49.47 | 30.5 | 24 | 18.7 | ||||||
cash-flows.row.deferred-income-tax | 46.42 | 3.1 | 13.2 | 28.7 | ||||||
cash-flows.row.stock-based-compensation | 2.05 | 0.8 | 1.2 | 1.2 | ||||||
cash-flows.row.change-in-working-capital | -29.34 | 46.2 | -14.3 | -29.9 | ||||||
cash-flows.row.account-receivables | -10.56 | 0 | 18.8 | -12.2 | ||||||
cash-flows.row.inventory | -17.62 | 15.5 | -33.1 | -17.7 | ||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-working-capital | -1.16 | 30.7 | 0 | 0 | ||||||
cash-flows.row.other-non-cash-items | 63.45 | 7.3 | -26.3 | -8.6 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 41.95 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | -128 | -56.7 | -75.1 | -74 | ||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-investing-activites | -9.95 | -2.8 | -3.3 | -6.9 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | -137.95 | -59.5 | -78.4 | -80.8 | ||||||
cash-flows.row.debt-repayment | -3.51 | -55.2 | -3.3 | -41.4 | ||||||
cash-flows.row.common-stock-issued | 13.79 | 0 | 17.2 | 182.1 | ||||||
cash-flows.row.common-stock-repurchased | -13.93 | 0 | -13.9 | -5.5 | ||||||
cash-flows.row.dividends-paid | -9.67 | 0 | -9.7 | -135.3 | ||||||
cash-flows.row.other-financing-activites | 71.01 | 139.7 | -17.2 | 130.9 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 57.68 | 84.5 | -26.9 | 130.9 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | -2.27 | -3.3 | 1.1 | 11.7 | ||||||
cash-flows.row.net-change-in-cash | -40.6 | 58.2 | -98.8 | 119.1 | ||||||
cash-flows.row.cash-at-end-of-period | 208.66 | 95.7 | 37.5 | 136.3 | ||||||
cash-flows.row.cash-at-beginning-of-period | 249.25 | 37.5 | 136.3 | 17.2 | ||||||
cash-flows.row.operating-cash-flow | 41.95 | 36.5 | 5.5 | 57.4 | ||||||
cash-flows.row.capital-expenditure | -128 | -56.7 | -75.1 | -74 | ||||||
cash-flows.row.free-cash-flow | -86.05 | -20.2 | -69.6 | -16.6 |
Resultatopgørelse række
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 601.35 | 320.4 | 281 | 282.1 | ||||||
income-statement-row.row.cost-of-revenue | 544.59 | 315.7 | 229 | 182.4 | ||||||
income-statement-row.row.gross-profit | 56.76 | 4.6 | 52 | 99.7 | ||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.research-development | 2.71 | - | - | - | ||||||
income-statement-row.row.selling-general-administrative | 70.54 | - | - | - | ||||||
income-statement-row.row.selling-and-marketing-expenses | 8.96 | - | - | - | ||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.operating-expenses | 99.79 | 41.1 | 42.3 | 37 | ||||||
income-statement-row.row.cost-and-expenses | 644.37 | 356.8 | 271.3 | 219.5 | ||||||
income-statement-row.row.interest-income | 8.77 | 0.1 | 2.1 | 2.8 | ||||||
income-statement-row.row.interest-expense | 0 | 5.6 | 2.1 | 2.8 | ||||||
income-statement-row.row.selling-and-marketing-expenses | 8.96 | - | - | - | ||||||
income-statement-row.row.total-other-income-expensenet | -29.37 | -21.8 | -5 | -7.6 | ||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.total-operating-expenses | -29.37 | -21.8 | -5 | -7.6 | ||||||
income-statement-row.row.interest-expense | 0 | 5.6 | 2.1 | 2.8 | ||||||
income-statement-row.row.depreciation-and-amortization | 42.05 | 30.5 | 20.5 | 16.1 | ||||||
income-statement-row.row.ebitda-caps | 20.74 | - | - | - | ||||||
income-statement-row.row.operating-income | -21.3 | -36.5 | 12.5 | 67.4 | ||||||
income-statement-row.row.income-before-tax | -50.68 | -58.2 | 7.6 | 59.8 | ||||||
income-statement-row.row.income-tax-expense | 12.19 | -6.8 | 0.2 | 12.6 | ||||||
income-statement-row.row.net-income | -43.67 | -51.4 | 7.8 | 47.3 |
Ofte stillede spørgsmål
Hvad er PolyPeptide Group AG (PPGN.SW) samlede aktiver?
PolyPeptide Group AG (PPGN.SW) samlede aktiver er 689088000.000.
Hvad er virksomhedens årlige omsætning?
Den årlige omsætning er 320372000.000.
Hvad er virksomhedens profitmargin?
Virksomhedens profitmargin er 0.015.
Hvad er virksomhedens frie pengestrøm?
Det frie cash flow er -0.498.
Hvad er virksomhedens nettoprofitmargin?
Nettofortjenstmargenen er -0.161.
Hvad er firmaets samlede omsætning?
Den samlede omsætning er -0.106.
Hvad er PolyPeptide Group AG (PPGN.SW) nettoresultat (nettoindkomst)?
Nettoresultatet (nettoindkomsten) er -51440000.000.
Hvad er virksomhedens samlede gæld?
Den samlede gæld er 113662000.000.
Hvad er tallet for driftsudgifter?
Driftsudgifterne er 41110000.000.
Hvad er firmaets likviditet?
Virksomhedens likviditet er 95706000.000.